GH vs TXG: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
GH is the larger of the two ($21.26B market cap): the incumbent the market prices for continued execution (-593.56x forward earnings, beta 1.66). TXG is the smaller challenger ($8.34B), priced similarly on forward earnings (731.16x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
GH vs TXG: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | GH | TXG | What it tells you |
|---|---|---|---|
| Market cap | $21.26B | $8.34B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -593.56 | 731.16 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.66 | 2.03 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 71% of range | 55% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how GH and TXG affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GH and TXG share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GH and TXG exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Guardant Health (GH) do?
Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue samples. Its business runs across three lines. Oncology, the largest, sells tests like Guardant360 (comprehensive genomic profiling that helps match patients to targeted therapies) and Guardant Reveal (a blood test for minimal residual disease, meaning traces of cancer left after treatment). Biopharma and Data sells testing, companion-diagnostic development, and real-world data to drugmakers. Screening is the newest and most-watched line: Shield is the first blood test to win full FDA approval as a primary screening option for colorectal cancer in average-risk adults 45 and older. In Q1 2026 the company reported ~$302 million in revenue, with oncology up 36% to ~$205 million on ~86,000 tests, biopharma and data at ~$53 million, and screening at ~$41.6 million on ~44,000 Shield tests (versus ~$5.7 million a year earlier).
What does 10x Genomics (TXG) do?
10x Genomics, Inc. (Nasdaq: TXG) builds instruments, reagents, and software for single-cell and spatial biology, the tools scientists use to read gene activity one cell at a time and map it across intact tissue. Its core franchises are Chromium (single-cell analysis), the Visium and Xenium spatial platforms, and the newly launched Atera in situ system (list price around $495,000, shipping in the second half of 2026). Revenue skews toward recurring consumables sold to academic labs, pharma and biotech research groups, and core genomics facilities, with instrument placements driving the razor-and-blade model over time.
GH vs TXG: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- GH drivers: Shield colorectal screening ramp; Core oncology growth and leverage.
- TXG drivers: Consumables-led recurring revenue; New platform launches (Atera and spatial).
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. For TXG, the biggest overhang is demand: U.S.
GH or TXG: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GH if you believe its drivers more; TXG if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GH and TXG guides.
GH vs TXG: the full fundamentals
GH. Figures are approximate and tied to the asOf date; verify live numbers before acting. GH trades near 18 times trailing sales, a multiple typical of a fast-growing, pre-profit diagnostics company, so the valuation is driven by expected future growth rather than current earnings. The stock more than doubled over the year to October 2026 but sits about 17% below its 52-week high of about $191, and the November 5 report (consensus revenue ~$351 million) plus the pace of Shield adoption and the 2027 breakeven timeline matter more than any single quarter.
TXG. 10x Genomics trades at roughly 15x sales while revenue is essentially flat and the company still runs a net loss, so the market is paying for future growth rather than current profits; the multiple has roughly doubled since mid-2026. Consensus for the September quarter, due November 5, 2026, is about $148M of revenue and an adjusted loss of $0.02 per share. The key swing factor remains whether academic and biopharma spending thaws, and Atera orders build, enough to restart instrument placements.
Headline figures (approximate, October 2026): GH shows revenue (ttm) ~$1.18 billion; Q2 2026 ~$335 million, up ~44% YoY, 2026 revenue outlook guided ~$1.30 to $1.32 billion earlier in 2026; consensus now ~$1.36 billion, gross margin (ttm) ~65%; operating margin ~-38%, net income (ttm) ~-$453 million loss; EPS ~-$3.50; TXG shows revenue (ttm) ~$617M, q2 2026 revenue ~$151M (~-13% YoY vs a settlement-boosted prior year), gross / operating margin ~70% / ~-15%, net income (ttm) ~-$75M.
The bottom line: GH vs TXG
GH and TXG are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GH and TXG exposure against your real portfolio. It is not an investment adviser.
Wondering how GH or TXG fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Guardant Health
Ask Walnut's AI anything about GH and see how it fits what you own.
FAQ
What is the difference between GH and TXG?
+
Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue samples. 10x Genomics, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is GH or TXG the better stock?
+
Neither is universally better. GH is the larger incumbent; TXG is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, GH or TXG?
+
On forward P/E (as of November 2026), GH trades at -593.56x and TXG at 731.16x, so GH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both GH and TXG?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of GH vs TXG?
+
GH: Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. Reimbursement is the central swing factor: coverage decisions, guideline inclusion, and per-test pricing (the $1,495 Medicare rate, private payer terms) can move sharply and are outside the company's control. Competition is intense from Exact Sciences (Cologuard in colorectal screening), Natera (minimal residual disease), and Roche's Foundation Medicine (genomic profiling), which pressures pricing and share. Shield's clinical sensitivity, roughly 84% overall but lower for early-stage and precancerous lesions, invites scrutiny versus colonoscopy. The stock also trades at a high price-to-sales multiple, so any slip in growth or the breakeven timeline can trigger large swings. Losses per share came in slightly worse than expected in Q2 2026 (-$0.42 vs -$0.39), and the balance sheet carried about $1.7 billion of debt against about $1.05 billion of cash at mid-2026. On October 15, 2026 the Patent Trial and Appeal Board rejected Guardant's challenge to a TwinStrand Biosciences duplex-sequencing patent, an intellectual-property dispute that remains open. TXG: The biggest overhang is demand: U.S. academic and NIH-linked research funding plus biopharma capital budgets have tightened sharply, and instrument sales dropped about 24% year over year, driving management's flat guidance. The company is still unprofitable on a net basis (about -$75M over the trailing twelve months), so the valuation, now near 15x sales after a 318% gain in 2026, leans heavily on a growth reacceleration that may not arrive on schedule. Consensus still expects 2026 revenue of only about $621M and 2027 revenue of about $684M. The stock is extremely volatile: its 52-week range runs from about $11.81 to $102.81, and it fell about 9% over the month to October 16. Competition is intensifying from Illumina, Bruker Spatial, Bio-Techne, Akoya, Vizgen, Bio-Rad, and newer single-cell entrants, and 10x has a long history of patent litigation whose settlements produced non-recurring revenue that will not repeat. New-platform adoption (Atera) is unproven at scale, and results can be lumpy quarter to quarter.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GH or TXG; figures are approximate and dated (as of November 2026). Verify current data before investing.